Hemophilia
FDA Licenses New Hemophilia Treatment
By admin - Posted on February 22nd, 2008
February 21, 2008 -- The U.S. Food and Drug Administration (FDA) today licensed a treatment for hemophilia A, a rare, hereditary blood-clotting disorder that affects approximately 15,000 individuals, almost exclusively males, in the United States.
The new treatment, called Xyntha Antihemophilic Factor (Recombinant) Plasma/Albumin Free, is a genetically engineered version of factor VIII, a protein essential for the clotting of blood. Factor VIII, known as an anti-hemophilic factor, is missing or decreased in patients with hemophilia A. » read more »
Latest stories
- Keating Economics
- Pelosi: The Legislation Has Failed But the Crisis Has Not Gone Away; We Must Work in a Bipartisan Way to Pass New Legislation
- Congressman Hoyer Statement Following Vote on Emergency Economic Stabilization Act
- Senator McCaskill Calls for Greater Accountability on Wall Street
- Senator Bob Casey Statement on Bailout Bill
- Senator Hillary Clinton Calls for Bipartisan Action on Economic Crisis
- Congress Passes Obama, Murkowski, Allen Bill to Ban Dangerous Mercury Exports
- Barack Obama Statement on Financial Plan Breakthrough
- Barack Obama Calls on VA Secretary to Provide Critical Data on Iraq and Afghanistan Veterans to Improve Veterans Services
- Statement from Senator Barack Obama on Washington Mutual
Yes We Can
Yes We Can:
